Epoetin beta
NeoRecormon (epoetin beta) is a protein pharmaceutical. Epoetin beta was first approved as Neorecormon on 1997-07-16. It has been approved in Europe to treat anemia, autologous blood transfusion, chronic kidney failure, and neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| epoch | OTC monograph not final | 2022-01-12 |
| epoch ava puhi moni anti-dandruff | C200263 | 2024-12-31 |
| epogen | Biologic Licensing Application | 2024-04-30 |
| mircera | Biologic Licensing Application | 2024-06-05 |
| nu skin epoch | OTC monograph final | 2009-12-14 |
| procrit | Biologic Licensing Application | 2024-05-09 |
| retacrit | Biologic Licensing Application | 2024-06-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
808 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 7 | 45 | 25 | 17 | 94 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | 10 | 6 | 15 | 34 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 9 | 5 | 16 | 33 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 4 | — | 1 | — | 5 |
| Preleukemia | D011289 | — | — | — | 4 | — | 1 | — | 5 |
| Syndrome | D013577 | — | — | — | 4 | — | 1 | — | 5 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | 2 | 1 | 5 |
| Hepatitis c | D006526 | — | B19.2 | — | 1 | 1 | 1 | — | 3 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | 1 | 1 | — | 3 |
| Kidney transplantation | D016030 | — | — | — | — | — | 2 | — | 2 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | 1 | — | — | 2 |
| Hepatitis | D006505 | — | K75.9 | — | 1 | 1 | — | — | 2 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 1 | 1 | — | — | 2 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 2 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Epoetin beta |
| INN | epoetin alfa |
| Description | Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
|
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 122312-54-3 |
| RxCUI | 105695 |
| ChEMBL ID | CHEMBL2109092 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00016 |
| UNII ID | 64FS3BFH5W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55,646 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epogen, Mircera, Procrit, Retacrit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49,350 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use